Comment on Ostrominski et al. Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations.

Related research

• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med · 2016 · 5096 citations
• Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med · 2021 · 3798 citations
• Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med · 2022 · 2783 citations
• Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med · 2023 · 2447 citations
• Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet · 2019 · 2402 citations
• A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med · 2021 · 1609 citations
• Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med · 2021 · 1567 citations
• Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med · 2019 · 1497 citations